Trial · NCT04274426
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). | Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier. | PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). |
| Secondary | OS | Up to 2.5 years. From date of randomization until date of death from any cause. | Overall survival |
| Secondary | ORR | Up to 2.5 years. From date of randomization to date of death death from any cause. | Objective response rate |
| Secondary | Efficacy regarding PFS | Up to 2.5 years. From date of randomization to date of death from any cause. | Efficacy regarding Progression Free Survival depending on histologic subtype |
| Secondary | Efficacy regarding OS | Up to 2.5 years. From date of randomization to date of death from any cause. | Efficacy regarding Overall Survival depending on histologic subtype |
| Secondary | Efficacy regarding ORR | Up to 2.5 years. From date of randomization to date of death from any cause. | Efficacy regarding Objective Response Rate depending on histologic subtype |
| Secondary | Serological progressive disease | Up to 2.5 years. From date of randomization to date of death death from any cause. | Time to serological progressive disease according to GCIG criteria |
| Secondary | Time to first subsequent treatment (TFST) | Up to 2.5 years. From date of randomization to date of death from any cause. | Time to first subsequent treatment (TFST) |
| Secondary | Time to second subsequent treatment (TSST) | Up to 2.5 years. From date of randomization until date of death from any cause. | Time to second subsequent treatment (TSST) |
| Secondary | Patient-reported outcomes | Up to 2.5 years. From date of randomization until date of death from any cause. | Quality of Life (EORTC C-30) |
| Secondary | Patient-reported outcomes | Up to 2.5 years. From date of randomization until date of death from any cause. | Quality of Life (EORTC OV28) |
| Secondary | Safety and tolerability | Up to 2.5 years. From date of randomization until date of death from any cause through study completion. | Safety and tolerability of the used drugs evaluated by NCI CTCAE v5.0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04274426/registered